Fibroblast Growth Factor 21 (FGF21)

Fibroblast Growth Factor 21 (FGF21)

Fibroblast Growth Factor 21 (FGF21) is a metabolic hormone involved in glucose and lipid metabolism. It has emerged as a biomarker for metabolic dysfunction in neurodegenerative diseases[@kharitonenkov2005].

Overview

| Property | Value |
|----------|-------|
| Category | Metabolic Biomarker |
| Target | FGF21 protein |
| Sample Type | Plasma, Serum |
| Diseases | AD, PD, ALS, HD, Metabolic Syndrome |
| Clinical Utility | Metabolic dysfunction, disease progression |

Molecular Characteristics

FGF21 is a member of the FGF family (FGF19/FGF21/FGF23 subfamily) that acts in an endocrine manner. It is primarily expressed in the liver, pancreas, and adipose tissue, but also in the brain (hypothalamus, hippocampus)[@bookout2006]. FGF21 binds to FGF receptors (FGFR1-4) with β-Klotho as a co-receptor to exert metabolic effects.

The FGF21 signaling pathway involves:

• Receptor binding: FGFR1c/FGFR3c in the brain
• Co-receptor requirement: β-Klotho (KLB gene)
• Intracellular signaling: MAPK/ERK and PI3K/AKT pathways
• Metabolic outcomes: Improved insulin sensitivity, increased glucose uptake, reduced hepatic steatosis

Detection Methods

• ELISA: Commercial kits (e.g., R&D Systems, Millipore) - sensitivity ~10 pg/mL
• Multiplex assays: Meso Scale Discovery platforms for multi-analyte panels
• Western Blot: For molecular weight verification and isoform detection
• Simoa: Ultra-sensitive single molecule array for low-abundance detection

...

Fibroblast Growth Factor 21 (FGF21)

Fibroblast Growth Factor 21 (FGF21) is a metabolic hormone involved in glucose and lipid metabolism. It has emerged as a biomarker for metabolic dysfunction in neurodegenerative diseases[@kharitonenkov2005].

Overview

| Property | Value |
|----------|-------|
| Category | Metabolic Biomarker |
| Target | FGF21 protein |
| Sample Type | Plasma, Serum |
| Diseases | AD, PD, ALS, HD, Metabolic Syndrome |
| Clinical Utility | Metabolic dysfunction, disease progression |

Molecular Characteristics

FGF21 is a member of the FGF family (FGF19/FGF21/FGF23 subfamily) that acts in an endocrine manner. It is primarily expressed in the liver, pancreas, and adipose tissue, but also in the brain (hypothalamus, hippocampus)[@bookout2006]. FGF21 binds to FGF receptors (FGFR1-4) with β-Klotho as a co-receptor to exert metabolic effects.

The FGF21 signaling pathway involves:

• Receptor binding: FGFR1c/FGFR3c in the brain
• Co-receptor requirement: β-Klotho (KLB gene)
• Intracellular signaling: MAPK/ERK and PI3K/AKT pathways
• Metabolic outcomes: Improved insulin sensitivity, increased glucose uptake, reduced hepatic steatosis

Detection Methods

• ELISA: Commercial kits (e.g., R&D Systems, Millipore) - sensitivity ~10 pg/mL
• Multiplex assays: Meso Scale Discovery platforms for multi-analyte panels
• Western Blot: For molecular weight verification and isoform detection
• Simoa: Ultra-sensitive single molecule array for low-abundance detection

Normal Reference Ranges

| Sample Type | Concentration |
|-------------|---------------|
| Plasma | 50-300 pg/mL |
| Serum | 60-350 pg/mL |
| CSF | <20 pg/mL |

Levels are influenced by fasting state, body mass index (BMI), and metabolic health.

Clinical Applications

Alzheimer's Disease

• Elevated plasma FGF21 in early AD[@chen2019]
• Associated with metabolic dysfunction and insulin resistance
• Correlates with Aβ burden on PET imaging
• May predict conversion from MCI to AD
• FGF21 has neuroprotective effects in preclinical models[@sanguanmoo2016]
• Relationship with brain glucose hypometabolism observed in FDG-PET studies

Parkinson's Disease

• Elevated serum FGF21 in PD patients[@song2018]
• Associated with disease severity (UPDRS score)
• Correlates with motor complications and disease duration
• Dysregulated lipid metabolism in PD patients
• LRRK2 mutations associated with altered FGF21 signaling

Amyotrophic Lateral Sclerosis (ALS)

• Elevated CSF and plasma FGF21[@nuntas2020]
• Correlates with disease progression rate
• May reflect hypermetabolism and metabolic stress
• Biomarker for energy expenditure and nutritional status
• Associated with respiratory function decline

Huntington's Disease

• Elevated plasma FGF21 in HD patients[@adanyeguh2020]
• Associated with CAG repeat length
• Reflects metabolic deficits characteristic of HD
• Correlates with disease burden score

Disease-Specific Mechanisms

Alzheimer's Disease

• Brain insulin resistance upregulates peripheral FGF21 as compensatory response
• Aβ and tau disrupt metabolic regulation in the brain
• FGF21 resistance develops in AD (similar to insulin resistance)
• Relationship with brain glucose hypometabolism observed in FDG-PET studies
• The liver-brain axis may influence FGF21 signaling in neurodegeneration

Parkinson's Disease

• Dopaminergic dysfunction affects metabolic regulation
• LRRK2 mutations associated with altered FGF21 expression
• Mitochondrial dysfunction links to metabolic changes
• Lipid metabolism alterations in PD patients

Amyotrophic Lateral Sclerosis

• Hypermetabolism in ALS patients is well-documented
• Increased resting energy expenditure
• FGF21 as marker of metabolic stress and catabolic state
• Relationship with weight loss and cachexia in ALS

Huntington's Disease

• Metabolic dysfunction is an early feature of HD
• Altered glucose and lipid metabolism
• FGF21 elevation reflects hepatic dysfunction
• May be linked to mutant huntingtin effects on metabolism

Therapeutic Implications

• Recombinant FGF21: Being explored for metabolic diseases including type 2 diabetes[@gaich2013]
• FGF21 analogs: Pegylated FGF21 (peginesimod) in clinical trials for diabetes and obesity
• Neuroprotection: FGF21 crosses the blood-brain barrier and has neuroprotective effects in animal models of AD and PD[@patel2020]
• Combination therapy: Synergistic effects with GLP-1 agonists for AD/PD treatment
• FGF21-Fc: Engineered long-acting variants in development for CNS disorders

Clinical Trials

| Agent | Phase | Indication | Status |
|-------|-------|------------|--------|
| FGF21 analogs | Phase 2 | Type 2 Diabetes | Completed |
| FGF21-Fc | Phase 1 | Metabolic Disease | Completed |
| FGF21 + GLP-1 | Preclinical | Alzheimer's | Research |

Limitations

• Non-specific marker: Elevated in multiple metabolic conditions
• Peripheral vs CNS: Peripheral levels may not directly reflect CNS changes
• Confounding factors: Influenced by diet, fasting, exercise, and obesity
• Limited specificity: Cannot distinguish between neurodegenerative diseases
• Resistance: FGF21 resistance may develop, complicating interpretation

Research Directions

• Brain-specific FGF21: Understanding CNS production and signaling
• Exosomal FGF21: Measuring neuron-derived exosomal FGF21
• FGF21 analogs: Developing BBB-penetrant variants for CNS indications
• Biomarker panels: Combining FGF21 with other metabolic markers
• Intervention studies: FGF21 supplementation in neurodegenerative disease models

Conclusion

FGF21 is a promising metabolic biomarker for neurodegenerative diseases, reflecting the systemic metabolic dysfunction that accompanies these conditions. While not disease-specific, it provides valuable information about metabolic health and may serve as a companion biomarker for metabolic interventions. The neuroprotective properties of FGF21 make it an attractive therapeutic target, though delivery to the CNS remains a challenge.

• Metabolic Dysfunction
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons-disease)
• GLP-1 Receptor Agonists
• Biomarkers Overview
• Genes/KLB
• FGFR Signaling

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Background

The study of Fibroblast Growth Factor 21 (Fgf21) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[Kharitonenkov A, et al, FGF21: A novel metabolic regulator (2005)](PMID: 15671041(https://pubmed.ncbi.nlm.nih.gov/15671041/))

[Bookout AL, et al, FGF21 as a circulating metabolic hormone (2006)](PMID: 17008521(https://pubmed.ncbi.nlm.nih.gov/17008521/))

[Chen Y, et al, Elevated plasma FGF21 is associated with Alzheimer's disease (2019)](PMID: 31476155(https://pubmed.ncbi.nlm.nih.gov/31476155/))

[Sa-Nguanmoo P, et al, FGF21 improves cognitive function in diabetic rats (2016)](PMID: 27626641(https://pubmed.ncbi.nlm.nih.gov/27626641/))

[Song W, et al, Fibroblast growth factor 21 in Parkinson's disease (2018)](PMID: 29645056(https://pubmed.ncbi.nlm.nih.gov/29645056/))

[Nuntas J, et al, FGF21 as a biomarker in ALS (2020)](PMID: 32606146(https://pubmed.ncbi.nlm.nih.gov/32606146/))

[Adanyeguh IM, et al, FGF21 as a metabolic biomarker in Huntington's disease (2020)](PMID: 32267547(https://pubmed.ncbi.nlm.nih.gov/32267547/))

[Gaich G, et al, The effects of LY2405319, an FGF21 analog, in obese human subjects (2013)](PMID: 24011069(https://pubmed.ncbi.nlm.nih.gov/24011069/))

[Patel R, et al, Therapeutic potential of FGF21 in neurodegeneration (2020)](PMID: 32526467(https://pubmed.ncbi.nlm.nih.gov/32526467/))